Boston, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in hybrid care enablement, announced that the company will participate in several investor conferences in September.
Ido Schoenberg, M.D., Amwell’s chairman and CEO, and Robert Shepardson, Amwell’s CFO, will participate in the following conferences via fireside chat and one-on-one meetings held throughout the day:
September 4, Morgan Stanley 22nd Annual Global Healthcare Conference in New York City; fireside chat at 1:50 p.m. ET.
September 5, Wells Fargo Healthcare Conference in Boston (one-on-one meetings only).
On September 10, Mr. Shepardson will participate in one-on-one investor meetings at the Baird Healthcare Conference in New York City, as well as a panel discussion during the TD Cowen 9th’s Annual FutureHealth Conference held at 2:20 p.m.ET at One Vanderbilt in New York City.
An audio webcast of the Morgan Stanley fireside chat and the TD Cowen panel will be available at investors.amwell.com.
About Amwell
Amwell is a leading hybrid care delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Amwell ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.
Last Trade: | US$10.97 |
Daily Change: | 0.68 6.61 |
Daily Volume: | 38,601 |
Market Cap: | US$149.960M |
January 15, 2025 December 18, 2024 October 30, 2024 October 08, 2024 July 31, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load